NDAVAGINALCREAM
Approved
Jan 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dienestrol is a non-steroidal synthetic estrogen cream approved in 1947 for vaginal administration. It is used to treat vaginal atrophy and related estrogenic deficiency symptoms in postmenopausal women. The drug works by providing local estrogen replacement to restore vaginal tissue health and function.
LOE Approaching
This legacy asset faces patent expiration; commercial teams should expect declining market share and transition focus to defending volume or repositioning in a crowded HRT market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Dienestrol in a LOE-approaching stage offers career experience in defensive commercial strategy, generic competition management, and lifecycle extension tactics. Roles focus on protecting market share and optimizing profitability rather than growth, making this suitable for professionals seeking mature asset management expertise.
Brand ManagerProduct Manager
Worked on DIENESTROL at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.